Ocular Therapeutix announced positive Phase 3 SOL-1 trial results for AXPAXLI, showing superior and durable outcomes in treating wet age-related macular degeneration (AMD). The company is advancing regulatory submission plans with the FDA and has initiated enrollment in a long-term extension trial (SOL-X). Financially, Ocular holds $666.7 million in cash, supporting operations into 2028, while continuing progress on additional trials including SOL-R and HELIOS-3. An Investor Day is scheduled for June 17, 2026, to provide further updates on clinical and commercial developments.
BioLineRx, a clinical-stage biopharmaceutical company, will release its Q1 2026 financial results on May 27, 2026. Analysts expect an earnings loss of $1.04 per share and revenue of $343,000, reflecting ongoing development costs typical for its growt...
Google Cloud Security used the Instruqt platform to train over 150 professionals on Agentic AI during the Google Next 2026 conference. Each participant worked in a dedicated Google Cloud Vertex AI environment to build and explore AI agents hands-on, ...
At Google Next 2026, Google Cloud Security used the Instruqt platform to train over 150 practitioners on Agentic AI. Each participant received a dedicated Vertex AI environment to build their own AI agents hands-on, moving beyond slide-based demos. T...
At Google Next 2026, Google Cloud Security used the Instruqt platform to train over 150 professionals in agentic AI capabilities. Each participant received a dedicated Google Cloud Vertex AI environment to build and explore AI agents hands-on, moving...
At the 2026 Google Next conference, Google Cloud Security used the Instruqt platform to provide hands-on Agentic AI training to over 150 practitioners. Each participant received a dedicated Google Cloud Vertex AI environment to build and explore AI a...
